Navigation Links
N.C. Biotech Center Launches Larger Loans
Date:7/9/2008

Support doubled to take product ideas to market

RESEARCH TRIANGLE PARK, N.C., July 9 /PRNewswire-USNewswire/ -- Start-up biotech companies may qualify for up to $1 million in loans under a program unveiled this week by the North Carolina Biotechnology Center.

The loans are part of an expanded program funded by the Biotechnology Center for companies in North Carolina. The funds give early-stage companies a boost before they become competitive for angel or venture-capital investment. Separate loans support company inception, certain types of research and corporate growth.

The overall dollar amounts are more than two times larger than in years past.

"Building a viable biotechnology company requires years of struggle and millions of dollars," said John Richert, vice president of the Business and Technology Development Program, "and the costs keep rising."

"So we've not only increased the caps on these offerings, but we've also made some revisions to fill funding gaps and stay ahead of the changing dynamics of the marketplace."

The revisions became effective July 1 and were a product of conversations with members of the venture-capital community, university technology-transfer offices and with entrepreneurs to learn how the Biotechnology Center could improve its support of companies at different stages of development.

Getting Started

The first change was to eliminate two programs that awarded either $25,000 or $50,000 to fund corporate spin-outs or university start-ups. Those two programs are now replaced with the Company Inception Loan of $50,000.

The business-inception package also includes a $50,000 Technology Enhancement Grant for technology-transfer offices at North Carolina universities.

"That's to help them make technologies they may have on their shelves more licensable," said Richert.

Supporting Research

In the research-loan offerings, the Biotechnology Center's Small Business Innovation Research Bridge Loans fill the gap between phases of federal SBIR funding. The loans are now capped at $150,000, twice as large as before. The maximum for Small Business Research Loans, which support applied research, has increased from $150,000 to $350,000.

Funding Early Growth

Company access to the Strategic Growth Loans has also been effectively doubled. A company meeting clear milestones defined in a $250,000 Strategic Growth Loan is now eligible for a second $250,000 infusion through the same program. Companies were formerly limited to one such award. The loans still require matching investment from a qualifying investment fund.

The Business and Technology Development Program has provided more than $16 million in loans and other support to more than 100 startup companies statewide since the Biotechnology Center was established in 1984.

That investment has resulted in more than $1.6 billion in additional dollars from venture capital, federal grants, cooperative business agreements and other sources. That's a return of $100 for every dollar invested - a major reason North Carolina is the third-largest biotechnology state in the United States.

The Biotechnology Center is a private, non-profit corporation supported by the N.C. General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business and education statewide.


'/>"/>
SOURCE North Carolina Biotechnology Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
2. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
3. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
4. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
5. N.C. Biotechnology Center Launches Industrial Fellowship Program
6. ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies
7. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
8. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
9. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
10. Rentschler Biotechnologie erweitert Kapazitten fr Produktion in Sugetierzellen
11. Rentschler Biotechnologie Extends Capacities for Mammalian Cell Culture Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... Operations. She brings years of expertise in establishing and leading clinical operations at ... a licensed occupational therapist, through a variety of leadership roles in Clinical Operations, ...
(Date:5/23/2017)... Massachusetts (PRWEB) , ... May 23, 2017 , ... ... making a splash at this year’s Bio-IT World Conference and Expo in ... Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also a ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare ... has opened an office in downtown Boston at 745 Atlantic Ave. , “We ... to generate evidence on the value they provide, not just to patients, but also ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology workflow ... at the Association for Pathology Informatics Annual Summit at the Wyndham ... its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):